{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:17:13Z","timestamp":1773332233319,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12185-018-02586-7","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T21:54:34Z","timestamp":1546466074000},"page":"286-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-4674","authenticated-orcid":false,"given":"Hiroki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kitadate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"2586_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1215\/15228517-5-2-104","volume":"5","author":"JM Baehring","year":"2003","unstructured":"Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro Oncol. 2003;5:104\u201315.","journal-title":"Neuro Oncol"},{"key":"2586_CR2","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1002\/cncr.26090","volume":"117","author":"K Matsue","year":"2011","unstructured":"Matsue K, Hayama BY, Iwama K, Koyama T, Fujiwara H, Yamakura M, et al. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. Cancer. 2011;117:4512\u201321.","journal-title":"Cancer"},{"key":"2586_CR3","first-page":"1011","volume":"19","author":"KR Maravilla","year":"1998","unstructured":"Maravilla KR, Bowen BC. Imaging of the peripheral nervous system: evaluation of peripheral neuropathy and plexopathy. Am J Neuroradiol. 1998;19:1011\u201323.","journal-title":"Am J Neuroradiol"},{"key":"2586_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2214\/ajr.169.4.9308489","volume":"169","author":"A Swarnkar","year":"1997","unstructured":"Swarnkar A, Fukui MB, Fink DJ, Rao GR. MR imaging of brachial plexopathy in neurolymphomatosis. Am J Roentgenol. 1997;169:1189\u201390.","journal-title":"Am J Roentgenol"},{"key":"2586_CR5","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1080\/10428194.2017.1312376","volume":"58","author":"JM Byun","year":"2017","unstructured":"Byun JM, Kim KH, Kim M, Kim TM, Jeon YK, Park JH, et al. Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. Leuk Lymphoma. 2017;58:2624\u201332.","journal-title":"Leuk Lymphoma"},{"key":"2586_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3988\/jcn.2016.12.3.274","volume":"12","author":"R Shree","year":"2016","unstructured":"Shree R, Goyal MK, Modi M, Gaspar BL, Radotra BD, Ahuja CK, et al. The diagnostic dilemma of neurolymphomatosis. J Clin Neurol. 2016;12:274\u201381.","journal-title":"J Clin Neurol"},{"key":"2586_CR7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00415-016-8190-4","volume":"263","author":"H Kinoshita","year":"2016","unstructured":"Kinoshita H, Yamakado H, Kitano T, Kitamura A, Yamashita H, Miyamoto M, et al. Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases. J Neurol. 2016;263:1719\u201326.","journal-title":"J Neurol"},{"key":"2586_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/neuonc\/nop021","volume":"12","author":"HK Gan","year":"2010","unstructured":"Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol. 2010;12:212\u20135.","journal-title":"Neuro Oncol"},{"key":"2586_CR9","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1182\/blood-2009-12-258210","volume":"115","author":"S Grisariu","year":"2010","unstructured":"Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2010;115:5005\u201311.","journal-title":"Blood"},{"key":"2586_CR10","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/cncr.20263","volume":"100","author":"IM Ghobrial","year":"2004","unstructured":"Ghobrial IM, Buadi F, Spinner RJ, Colgan JP, Wolanskyj AP, Dyck PJ, et al. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer. 2004;100:2403\u20137.","journal-title":"Cancer"},{"key":"2586_CR11","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512\u201320.","journal-title":"Lancet"},{"key":"2586_CR12","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2302::AID-CNCR18>3.0.CO;2-0","volume":"77","author":"A Stamatoullas","year":"1996","unstructured":"Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Cancer. 1996;77:2302\u20137.","journal-title":"Cancer"},{"key":"2586_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"2586_CR14","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","volume":"51","author":"AK Gopal","year":"2010","unstructured":"Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma. 2010;51:1523\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2586_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547\u201361.","journal-title":"J Clin Oncol"},{"key":"2586_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014the Southwest Oncology Group. J Clin Oncol. 2009;27:114\u20139.","journal-title":"J Clin Oncol"},{"key":"2586_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00277-010-1104-0","volume":"90","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, et al. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol. 2011;90:539\u201346.","journal-title":"Ann Hematol"},{"key":"2586_CR18","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283\u201390.","journal-title":"Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-02586-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-02586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-02586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:27:41Z","timestamp":1577993261000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-02586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-02586-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants in this study were in accordance with the ethical standards of the institutional and national research committee as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}